# GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

> **NCT01176513** · PHASE2 · TERMINATED · sponsor: **GE Healthcare** · enrollment: 25 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** GE-148 (18F)

## Key facts

- **NCT ID:** NCT01176513
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Lack of Subject enrollment
- **Last updated:** 2014-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01176513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01176513, "GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01176513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*